BIOA (Bioage Labs) Issuance of Debt : $0.00 Mil (TTM As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Bioage Labs Issuance of Debt?

Bioage Labs's Issuance of Debt for the three months ended in Dec. 2024 was $0.00 Mil.

Bioage Labs's Issuance of Debt for the trailing twelve months (TTM) ended in Dec. 2024 was $0.00 Mil.

Bioage Labs Issuance of Debt Historical Data

The historical data trend for Bioage Labs's Issuance of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bioage Labs Issuance of Debt Chart

Bioage Labs Annual Data

Trend

Dec22

Dec23

Dec24

Issuance of Debt

2.50

36.00

Bioage Labs Quarterly Data
	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Issuance of Debt	Get a 7-Day Free Trial				-	-	-	-	-

Bioage Labs Issuance of Debt Calculation

Issuance of Debt represents all the cash inflow from debt, including both long-term debt and short-term debt.

Issuance of Debt for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Bioage Labs Issuance of Debt Related Terms

Thank you for viewing the detailed overview of Bioage Labs's Issuance of Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Bioage Labs Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Bioage Labs Inc (NAS:BIOA) » Definitions » Issuance of Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

1445A South 50th Street, Richmond, CA, USA, 94804

Website

https://www.bioagelabs.com

Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its focus is metabolic disease, one of the greatest healthcare challenges. Its Products are Azelaprag (BGE-105), an apelin receptor APJ agonist that increases weight loss and improves body composition combined with incretin drugs. and BGE-100 is targeting metabolic diseases and neuroinflammation.